These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 22728920)

  • 1. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for the design and synthesis of selective HDAC inhibitors.
    Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
    Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of tumor cells by targeting histone deacetylases.
    Perego P; Zuco V; Gatti L; Zunino F
    Biochem Pharmacol; 2012 Apr; 83(8):987-94. PubMed ID: 22120677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes.
    Li Y; Shin D; Kwon SH
    FEBS J; 2013 Feb; 280(3):775-93. PubMed ID: 23181831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
    Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
    ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting class I histone deacetylases in cancer therapy.
    Delcuve GP; Khan DH; Davie JR
    Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoform-specific histone deacetylase inhibitors: the next step?
    Balasubramanian S; Verner E; Buggy JJ
    Cancer Lett; 2009 Aug; 280(2):211-21. PubMed ID: 19289255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.
    Lee AY; Paweletz CP; Pollock RM; Settlage RE; Cruz JC; Secrist JP; Miller TA; Stanton MG; Kral AM; Ozerova ND; Meng F; Yates NA; Richon V; Hendrickson RC
    J Proteome Res; 2008 Dec; 7(12):5177-86. PubMed ID: 19367703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inside HDAC with HDAC inhibitors.
    Bertrand P
    Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia.
    Weïwer M; Lewis MC; Wagner FF; Holson EB
    Future Med Chem; 2013 Sep; 5(13):1491-508. PubMed ID: 24024943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
    Mahboobi S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
    J Med Chem; 2010 Dec; 53(24):8546-55. PubMed ID: 21080629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.